Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma

Momoko Kurihara, Hiroki Kabata, Misato Irie, Koichi Fukunaga

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)


Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that plays a vital role in the induction of type 2 inflammation via both innate and acquired immune cascades. Tezepelumab, a human IgG2 monoclonal antibody that inhibits the binding of TSLP to the TSLP receptor, is the latest biologic for asthma. To evaluate the efficacy and mechanism of tezepelumab in asthma, the PATHWAY, NAVIGATOR, NOZOMI, UPSTREAM, CASCADE, SOURCE, and DESTINATION studies have been conducted. These results suggested that tezepelumab is a broad-target biologic, which is expected to be effective in patients with poorly controlled moderate to severe asthma regardless of the phenotype, although its efficacy in oral corticosteroids-dependent asthma, biological mechanism in non-type 2 phenotype, and long-term safety remain unknown. In this review, we summarize the results of clinical trials of tezepelumab in asthma and discuss the differences between tezepelumab and other biologics.

Original languageEnglish
Pages (from-to)24-30
Number of pages7
JournalAllergology International
Issue number1
Publication statusPublished - 2023 Jan


  • Biologics
  • ILC2s
  • Randomized clinical trials
  • Severe asthma
  • Type 2 inflammation

ASJC Scopus subject areas

  • Immunology and Allergy


Dive into the research topics of 'Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma'. Together they form a unique fingerprint.

Cite this